CD8 T Cell-Initiated Vascular Endothelial Growth Factor Expression Promotes Central Nervous System Vascular Permeability under Neuroinflammatory Conditions

Georgette L. Suidan, Jonathan W. Dickerson, Yi Chen, Jeremiah R. McDole, Pulak Tripathi, Istvan Pirko, Kim B. Seroogy and Aaron J. Johnson

J Immunol 2010; 184:1031-1040; Prepublished online 11 December 2009; doi: 10.4049/jimmunol.0902773
http://www.jimmunol.org/content/184/2/1031

References
This article cites 70 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/184/2/1031.full#ref-list-1

Subscription
Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Deregulation of the blood-brain barrier (BBB) is a hallmark feature of numerous neurologic disorders as diverse as multiple sclerosis, stroke, epilepsy, viral hemorrhagic fevers, cerebral malaria, and acute hemorrhagic leukoencephalitis. CD8 T cells are one immune cell type that have been implicated in promoting vascular permeability in these conditions. Our laboratory has created a murine model of CD8 T cell-mediated CNS vascular permeability using a variation of the Theiler’s murine encephalomyelitis virus system traditionally used to study multiple sclerosis. Previously, we demonstrated that CD8 T cells have the capacity to initiate astrocyte activation, cerebral endothelial cell tight junction protein alterations and CNS vascular permeability through a perforin-dependent process. To address the downstream mechanism by which CD8 T cells promote BBB dysregulation, in this study, we assess the role of vascular endothelial growth factor (VEGF) expression in this model. We demonstrate that neuronal expression of VEGF is significantly upregulated prior to, and coinciding with, CNS vascular permeability. Phosphorylation of fetal liver kinase-1 is significantly increased early in this process indicating activation of this receptor. Specific inhibition of neuropilin-1 significantly reduced CNS vascular permeability and fetal liver kinase-1 activation, and preserved levels of the cerebral endothelial cell tight junction protein occludin. Our data demonstrate that CD8 T cells initiate neuronal expression of VEGF in the CNS under neuroinflammatory conditions, and that VEGF may be a viable therapeutic target in neurologic disease characterized by inflammation-induced BBB disruption.

The Journal of Immunology, 2010, 184: 1031–1040.

Copyright © 2010 by The American Association of Immunologists, Inc. 0022-1767/10/$16.00

www.jimmunol.org/cgi/doi/10.4049/jimmunol.0902773
vascular-permeating event that is 50,000-fold more potent than histamine (25–28). After insult to the CNS, altered expression of VEGF and its receptors, FMS-related tyrosine kinase-1 and fetal liver kinase-1 (flk-1), has been observed in various pathological conditions such as ischemia, MS, viral infection, and injury (29–35). On binding VEGF, flk-1 dimerizes and undergoes phosphorylation at several tyrosine residues. The ensuing signal transduction though flk-1 promotes angiogenesis and vascular permeability, strongly implicating a role for VEGF in BBB disruption (28). A complete mechanism by which VEGF contributes to BBB dysregulation under neuroinflammatory conditions has yet to be elucidated (36–38). However, because of its vascular permeating effects in previous studies, we hypothesized that VEGF expression in the CNS contributes to CEC tight junction changes and BBB disruption during neuroinflammatory conditions. Using the PIFS model of CNS vascular permeability, we addressed the timing and downstream mechanisms by which VEGF promotes vascular permeability in the brain. The studies put forward in this paper demonstrate that VEGF contributes to CNS vascular permeability in the PIFS model. We further link VEGF binding to the flk-1 receptor to downregulation of the tight junction protein occludin. Our findings further imply that VEGF inhibition may have therapeutic implications for neurologic diseases characterized by neuroinflammation and BBB alterations.

Materials and Methods

Animals

C57BL/6 (strain no. 000664) and C57BL/6 Prf1−/− (Prf1−/−, perforin-deficient; strain no. 002407) mice were obtained from The Jackson Laboratory (Bar Harbor, ME) at 6 wk of age. Animals were given food and water ad libitum. All experiments were approved by the Institutional Animal Care and Use Committee of the University of Cincinnati (Protocol 06-10-09-01).

Induction of CNS vascular permeability using the PIFS model

CNS vascular permeability was induced as described previously (19, 22). Briefly, C57BL/6 mice were infected i.c. with 2 × 10^6 PFU Daniel’s strain of TMEV. Seven days post-TMEV infection, mice were injected i.v. with 0.1 mg VP2121–130 (FHAGSLLVFM) (GenScript, Piscataway, NJ) (19) and euthanized 0, 2, 4, 12, and 24 h (n = 4 mice for each time point) post-administration of VP2121–130. Brains were excised, frozen on dry ice, and stored at −80˚C. The brains were administered FITC-albumin i.v. Mice were euthanized at 12 h post-injection, and the contralateral hemisphere was processed for FITC-albumin permeability assay.

Neuropilin-1 inhibition with ATWLPPR peptide

C57BL/6 mice were infected i.c. with 2 × 10^6 PFU Daniel’s strain of TMEV. Seven days post-TMEV infection, mice were injected i.v. with 0.1 mg VP2121–130 or 0.1 mg E7 control peptide (19). ATWLPPR peptide at 1 mg or 3 mg, PBS (vehicle control) or 3 mg of RAPTLWP (scrambled peptide control) (GenScript), was i.v. injected via the tail vein 30 min prior to VP2121–130 administration, and 3, 6, and 9 h postadministration of VP2121–130 (n = 6 mice per group). One hour prior to brain harvest, mice were administered FITC-albumin i.v. Mice were euthanized 12 h post-administration of VP2121–130 or E7 control peptide. Brains were harvested, the hemisphere ipsilateral to TMEV infection was processed for FITC-albumin leakage, and the contralateral hemisphere was processed for Western blot analysis of occludin protein levels.

FITC-albumin permeability assay

Mice were injected i.v. via the tail vein with 10 mg FITC-albumin (Sigma-Aldrich, St. Louis, MO) 1 h prior to harvest. Fresh-frozen brains were sectioned (10-μm thickness) in a −20˚C Microm cryostat (Microm International GmbH, Walldorf, Germany) and thaw-mounted onto VWR micro slides (VWR International, West Chester, PA). Mounted sections were stored at −20˚C. All sections not mounted on slides were used to make homogenates as described in the Western blot section (22). Homogenates were normalized for protein using the bicinchoninic acid protein assay (Pierce, Rockford, IL) and read on a fluorescent plate reader at 488 nm excitation and 525 nm emission to detect FITC-albumin leakage into the brain. Data were collected using SpectraMax software (Molecular Devices, Sunnyvale, CA).

Western blots for VEGF and phosphorylated flk-1

Brain tissue samples were lysed in radioimmunoprecipitation assay buffer (10 mmol/l Tris, 140 mmol/l NaCl, 1% Triton X-100, 1% Na deoxycholate, 0.1% SDS, and protease inhibitor mixture [Pierce] pH 7.5) and centrifugated for 30 min at 10,000 rpm. Samples were normalized using the bicinchoninic acid protein assay and prepared using the method of Laemmli (39). Thirty microliters of sample were separated on an 8% gel run on 4–20% Tris-HCl gels (Bio-Rad, Hercules, CA) and run using Tris-HCl running buffer. Gels were transferred onto Immobilon polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA) using Tris transfer buffer. Blots were blocked for 1 h in 10% PBS-T milk and overnight at 4˚C in PhosphoDetect rabbit anti-VEGFR2 pTyr(1044/1059) (1:1000) (Calbiochem). Goat anti-rabbit conjugated to HRP (Santa Cruz Biotechnology, Santa Cruz, CA) was used to detect primary Ab. Western blot films were analyzed using OD measurements (Scion Image software [National Institutes of Health]). Background was subtracted from each band and data are expressed in arbitrary units (AU).

MicrovesSEL isolation and tight junction Western blots

MicrovesSEL isolation was based on the protocol previously described by Brooks et al. (40). Briefly, brain hemispheres contralateral to the intracranial TMEV injection site were homogenized in microvesSEL isolation buffer. 26% dextran was added and samples were centrifuged for 10 min at 5000 g. 5600 × g (SS-34 rotor, Sorvall, Ramsey, MN). Supernatants were discarded and the pellet was resuspended in microvesSEL isolation buffer. Samples were centrifuged at 5000 × g for 10 min. Pellets were resuspended in 6 M urea and digested overnight at 4˚C. Protein concentration was determined using a BSA standard curve and 34 μg was added per well to 4–20% Tris-HCl gels (Bio-Rad). For tight junction analysis, blots were probed using mouse anti-occludin (1:5000) ( Fitzgerald Industries International, Concord, MA) or rabbit anti-occludin (1:500) (Zymed Laboratories, San Francisco, CA). Goat anti-rabbit conjugated to HRP (Santa Cruz Biotechnology) or goat anti-mouse conjugated to horseradish-peroxidase (Santa Cruz Biotechnology) was used to detect primary Ab. Blots were developed and analyzed as described previously in the Western blot section. Occludin samples were normalized for protein with GAPDH values.

In situ hybridization

Fresh-frozen brains were mounted onto TBS tissue freezing medium (Ted Pella, Redding, CA) and frozen in powdered dry ice. The brains were sectioned (at 10-μm thickness) in a Microm cryostat, thaw-mounted onto VWR micro slides, and the sections were stored at −20˚C until hybridization. SemiaDJacent sections throughout the brain were hybridized with [35S]-labeled cDNA sense and antisense probes for detection and localization of VEGF mRNA according to our previously published protocol (41–43). The VEGF cDNA plasmid [kindly provided by L.F. Brown, Harvard University (44)] was contained in a pGEM3 vector and consisted of 393 bp. Labeled probes were prepared by in vitro transcription from linearized cDNA plasmids using the proper RNA polymerase (T7 for antisense and SP6 for sense) in the presence of excess [35S]-UTP (PerkinElmer, Waltham, MA) and were generated as previously described (41). Slide-mounted sections were hybridized overnight at 60˚C in hybridization mixture containing the [35S]-labeled probe at a concentration of 1 × 10⁶ cpm/50 μl/slide. After posthybridization treatment, slides were exposed to BioMax MR film (Kodak, Rochester, NY) for 8 d for generation of film autoradiographs. The films were developed with Kodak GPX developer and fixer. Semiquantitative analysis of the hippocampal dentate granule cell islets from the hemisphere of TMEV infection was performed using OD measurements (Scion Image software [National Institutes of Health]). The mean corrected gray levels were generated by subtracting a background measurement (taken from a nontissue-containing area on the same slide) from the OD in the dentate gyrus for each section. To provide cellular resolution, slides were then dipped in Kodak NTB autoradiography emulsion, exposed for 20 d, and then developed with Kodak D19 developer. These sections were then etched with 0.01% periodic acid for 24 h and covered with a coverslip for further analysis. Additional sections hybridized with the [35S]-labeled control sense probe resulted in no specific cellular labeling.

Immunofluorescent microscopy

Fresh-frozen brains were sectioned (10-μm thickness) in a −20˚C Microm cryostat and thaw-mounted onto VWR micro slides. Mounted sections were

Downloaded from http://www.jimmunol.org/ by guest on August 31, 2017
stored at −20°C. Tissue sections were fixed in cold 95% ethanol at 4°C for 15 min and washed with repeated changes in 0.1 M PBS for 30 min. Sections were blocked in 10% normal goat serum (in 0.1 M PBS + 0.05% Triton X-100) for 1 h. Sections were incubated in mouse antineuronal nuclei (NeuN) (1:1000) (Chemicon Millipore, Billerica, MA) and rat anti-CD8 α (1:1000) (AbD Serotec, Raleigh, NC) or rabbit anti-VEGF (1:200) (Calbiochem) overnight at 4°C in humid chamber. Sections were washed in 0.1 M PBS for 1 h and incubated in Alexa Fluor 647 goat anti-mouse IgG (1:750; Invitrogen, Carlsbad, CA), Alexa Fluor 555 goat anti-rat IgG (1:750; Invitrogen), or Alexa Fluor 647 goat anti-rabbit IgG (1:750; Invitrogen) for 4 h at room temperature. Slides were washed in 0.1 M PBS at 4°C overnight. Slides were incubated in 70%, 95%, and 100% ethanol for 3 min each and xylene for 5 min. Slides were coverslipped using Vectashield mounting medium for fluorescence (H-1000; Vector Labs, Burlingame, CA). Sections were imaged at room temperature at ×20 magnification using a Zeiss LSM 510 laser scanning confocal microscope at the Center for Biological Microscopy at the University of Cincinnati, College of Medicine, and Zeiss LSM 510 Image Browser version 4.0.0.241 (Carl Zeiss Micro Imaging, Oberkochen, Germany).

**Magnetic resonance imaging**

Animal handling and imaging were in compliance with Children’s Hospital Research Foundation Institutional Animal Care and Use Committee protocol 7A40435 approved March 8, 2008. Groups of four mice were sedated using 1.5% isoflurane delivered with 0.4 l/min of medical air. Magnetic resonance imaging (MRI) was performed on a Bruker 70/530 USR Biospec microimager/spectrometer (Bruker Biospin, Ettlingen, Germany) using a B-GA12 gradient insert (400 mT/m), 38 mm linear proton volume. For body scans, T1-weighted spin-echo images (TR/TE = 500/10 ms, field of view = 2.56 × 2.56 cm, matrix = 256 × 128) with two averages were used. The resulting spatial resolution is 100 × 200 μm with a 1-mm slice thickness. For brain scans, T1-weighted spin-echo sequences (TR 200 ms, TE 10 ms, field of view: 4 × 2.5 × 2.5 cm, matrix: 256 × 128 × 128, NEX 2) were used to determine the overall volume of gadolinium-enhancing areas (areas of increased BBB permeability). The mice were first imaged without contrast, removed from the scanner, and administered 0.1 mM/kg gadodiamide dimeglumine (Magnrevist, Berlex Laboratories, Montville, NJ) via tail vein injection, inserted back into the scanner and the imaging protocol was repeated.

**Statistical analysis**

Mean and SE values for FITC-albumin measurements, Western blot measurements, and in situ hybridization measurements were calculated using software program SigmaStat (SYSTAT Software, Chicago, IL). Bar graphs with SE values were plotted on software program SigmaPlot (SYSTAT Software). To determine significance between groups, a Student t test was performed using SigmaPlot with the exception of occludin Western blots corrected for GAPDH in which a rank sum test was performed using SigmaStat.

**Results**

**CD8 T cell-mediated vascular permeability is specific to the CNS in this model**

In the PIFS model of BBB disruption, the majority of brain-infiltrating CD8 T cells are specific for the immunodominant D3:VP2121–130 epitope in C57BL/6 mice (22, 23). At 7 d post-TMEV infection, this CD8 T cell expansion is predominantly localized to the CNS and not in peripheral lymphoid compartments (19, 23). To determine whether vascular permeability in the PIFS model was also exclusively localized to the CNS, we used 7 Tesla whole body MRI 24 h post-administration of VP2121–130 peptide to induce BBB disruption or mock E7 control peptide. Prior to scanning, gadolinium was i.v. injected to enable visualization of vascular leakage in major organs. As previously reported using contrast-enhanced T1-weighted MRI at 24 h post-VP2121–130 administration, we observe extensive gadolinium leakage into the brain but not into mock E7 peptide-administered controls (Fig. 1A, 1D show a representative mouse of four animals scanned) (22, 45). However, whole body scans revealed an absence of vascular permeability outside the CNS in both animals administered VP2121–130 peptide that were symptomatic for PIFS (Fig. 1E, 1F) or mock E7 peptide-treated controls (Fig. 1B, 1C, four animals scanned).

Therefore, consistent with our previous histological analysis of pathology in this model (19), this approach demonstrated that vascular permeability induced with PIFS was not systemic, but rather localized exclusively to the brain, the sight of D3:VP2121–130 epitope-specific CD8 T cell expansion.

Using FITC-albumin leakage as a marker for BBB disruption, we have demonstrated that Ag-specific CD8 T cells initiate BBB disruption (22). To determine the location of CD8 T cells in the CNS during acute TMEV infection, we used immunofluorescent confocal microscopy. Through an analysis of CNS tissue derived from groups of four animals, we determined that CD8+ cells were prevalent throughout the brain during acute TMEV infection. Shown are CD8+ cells infiltrating the hippocampal region (neurons in the stratum granulosum [SG] of the hippocampal dentate gyrus are identified with NeuN staining in blue) in a representative seven day TMEV-infected animal (n = 4 animals, Fig. 2A,2C, 2D). We also demonstrate that 4 h post-administration of VP2121–130 there is mild leakage of FITC-albumin (green) from vasculature in the hippocampus where CD8+ cells are found in close proximity to both blood vessels and neuronal cell bodies (n = 4 mice, Fig. 2B, 2E, 2F). This analysis, although not definitive in determining specific molecular interactions, demonstrated that CD8+ cells are colocalizing to both neurons and areas of vascular permeability.

**VEGF is expressed prior to peak levels of FITC-albumin leakage into the CNS**

VEGF cytokine expression in the CNS is a putative downstream mechanism by which inflammation could promote CNS vascular permeability (27, 38, 46). To determine the extent this cytokine was upregulated during CD8 T cell-mediated CNS vascular permeability, we assessed VEGF protein levels and FITC-albumin leakage into the brain at 0, 2, 4, 12, and 24 h post-VP2121–130 peptide administration (n = 4 per group). We determined that the 45 kDa form of VEGF protein was significantly increased within 4 h postadministration of VP2121–130 peptide when compared with 0 h controls (n = 4 per group; p = 0.004) (Fig. 3B). VEGF protein levels remained significantly elevated at 12 (n = 4; p < 0.01) and 24 (n = 4; p = 0.01) h postadministration of VP2121–130 peptide. CNS vascular permeability in the brain followed similar kinetics as VEGF expression in that a strong trend toward increased leakage of FITC-albumin was observed at 4 h postadministration.
of VP2121–130 peptide ($n = 4; p = 0.06$). This increase in FITC-albumin leakage became significantly higher than 0 h baseline controls at the 12 h and 24 h time points ($n = 4; p < 0.01$) (Fig. 3B). Concomitant with increased VEGF levels and vascular permeability was increased phosphorylation of VEGF receptor flk-1 in brain tissue (Fig. 3C). This significant increase in flk-1 phosphorylation occurred at 4 h postadministration of VP2121–130 peptide and remained significantly increased at the 12 and 24 h time points ($n = 4; p < 0.01$ when compared with 0 h baseline controls for all groups). The conclusion from these studies was that increased VEGF protein and flk-1 phosphorylation was coinciding with CNS vascular permeability after induction of Ag-specific CD8 T cell-mediated vascular permeability.

Neurons are a major source of VEGF expression in the CNS after induction of CD8 T cell-mediated CNS vascular permeability

To determine the cellular source of VEGF during CNS vascular permeability, we used in situ hybridization to label VEGF mRNA. Gross analysis of coronal brain sections from film autoradiograms revealed that VEGF mRNA expression was increased by 2 h postadministration of VP2121–130 when compared with uninfected and 0 h baseline controls (Fig. 4). The intensity of VEGF mRNA labeling remained increased at 4, 12, and 24 h postadministration of VP2121–130 peptide (Fig. 4). Because the hippocampus is an area with extensive FITC-albumin leakage and high levels of VEGF protein translation, we semiquantitatively analyzed the SG of the hippocampal dentate gyrus to determine at which time points VEGF mRNA expression was significantly upregulated in this brain region. In Fig. 4G, we demonstrate that 2 h postadministration of VP2121–130, VEGF mRNA labeling is significantly increased in this area of the brain when compared with the 0 h time point (0, 2 h; $n = 4; p < 0.001$) and continues to be significant at the 4 h ($n = 4; p < 0.001$), 12 h ($n = 4; p < 0.001$), and 24 h ($n = 4; p < 0.001$) time points. We also observed no significant differences in VEGF mRNA expression between uninfected mouse brain, TMEV-infected 0 h control, and sham PBS-injected animals ($n = 4$ per group, Fig. 4G), demonstrating that the method of i.c. infection does not elicit VEGF mRNA upregulation in the SG.

Upon further analysis of the hippocampus, we determined that neurons were a major source of VEGF expression during CNS vascular permeability. In Fig. 4H and 4I, we present VEGF mRNA emulsion autoradiograms of cresyl violet (Nissl)-stained sections. A cell was considered to express VEGF mRNA if there was a concentration of silver grains clustered over the cell body. The vast majority of VEGF cRNA-hybridizing cells within the hippocampal formation displayed Nissl-staining characteristics of neurons (e.g., the small, densely packed granule cells of the dentate gyrus SG; the larger pale-staining nuclei of hilar neurons). Increased expression of VEGF mRNA in the SG did not occur evenly throughout the dentate, but rather was patchy in appearance (Fig. 4H). In Fig. 4I, we demonstrate morphologically that primarily small granule cells of the hippocampal dentate gyrus, as well as a subpopulation of adjacent hilar neurons, are positive for VEGF mRNA. Patchy expression of VEGF mRNA was also observed within some of the large, pale-staining pyramidal cells of the CA1 and CA3 stratum pyramidale (not shown in Fig. 4H, 4I). In addition, occasional examples of hybridization over cells with Nissl-staining characteristics of glia (e.g., small, dark nuclei) can be found within the hippocampus, such as within the molecular layers. Thus, it cannot be ruled out that infrequent glia (i.e., astrocytes, microglia) also express VEGF mRNA. We did not, however, observe leucocyte morphologies that expressed VEGF mRNA. However, these in situ hybridization data strongly imply that the major cell type expressing VEGF in the hippocampus is neuronal. Immunofluorescent staining of VEGF protein and the neuronal marker NeuN further confirmed that neurons were a major source of VEGF protein during BBB disruption (Fig. 4J, 4K, 4M). Similar to the in situ mRNA analysis, expression of VEGF protein by neurons was patchy throughout the hippocampal region.

Inhibition of neuropilin-1 with ATWLPPR peptide reduces flk-1 phosphorylation and CNS vascular permeability

To determine whether CNS vascular permeability was mediated through VEGF-related signal transduction, we administered the neuropilin-1 (NRP-1) inhibitor, ATWLPPR. NRP-1 is a coreceptor for the VEGF receptor flk-1. Dimerization of these two receptors has been shown to enhance interaction of VEGF with flk-1, amplifying downstream signal transduction (47–49). In this experiment, we measured levels of FITC-albumin leakage into the brain in 7-d TMEV-infected C57BL/6 mice administered VP2121–130 peptide to induce CNS vascular permeability. These animals received either a 1-mg or 3-mg dose regimen of VEGF inhibitor ATWLPPR, sterile PBS, or a 3-mg dose regimen of scrambled (RAPTLWP) peptide mock treatment control. One group was
administered mock control E7 peptide i.v. to serve as an additional infected control in which CD8 T cells were not stimulated (22). One hour after FITC-albumin injection, mice were harvested to assess CNS vascular permeability as previously described (Fig. 5A) (22). Treatment with PBS, mock peptide RAPTLWP, and 1 mg doses of ATWLPPR resulted in significant increases in FITC-albumin leakage into the brain when compared with negative control E7 peptide-treated animals. However, treatment with 3 mg doses of ATWLPPR significantly decreased leakage of FITC-albumin into the brain when compared with PBS- and RAPTLWP-treated animals (n = 9; p < 0.01). There was no significant difference between mock E7 peptide-treated and 3 mg ATWLPPR-treated animals (E7 n = 6, 3 mg n = 9; p = 0.23). This experiment demonstrated that administration of NRP-1 inhibitor reduced CD8 T cell-induced CNS vascular permeability.

NRP-1 is a non-tyrosine kinase coreceptor for VEGF that has been shown to enhance flk-1-mediated processes (47). Previous reports have shown that peptide inhibitor, ATWLPPR, inhibits binding of VEGF to NRP-1, decreasing flk-1 activation (50, 51). To determine, in vivo, whether systemic ATWLPPR administration reduces flk-1 activation in the brain when compared with negative control E7 peptide-treated animals (n = 9; p < 0.01). There was no significant difference between mock E7 peptide-treated and 3 mg ATWLPPR-treated animals (E7 n = 6, 3 mg n = 9; p = 0.23). This experiment demonstrated that administration of NRP-1 inhibitor reduced CD8 T cell-induced CNS vascular permeability.

Inhibition of NRP-1 with ATWLPPR peptide preserves BBB tight junction protein occludin

Inhibition of CNS vascular permeability through administration of NRP-1 inhibitor suggested that BBB integrity was preserved. Our group previously reported alteration of the CEC BBB tight junction protein occludin after CD8 T cell-induced CNS vascular permeability (22). In this previous study, we determined that 4 h postadministration of VP2121–130 peptide, occludin levels were significantly decreased in the brain coinciding with the onset of vascular permeability (22). We therefore examined occludin levels in microvessel isolations obtained from animals treated with 3 mg doses of ATWLPPR as compared with sterile PBS controls. In accordance with having preserved vascular integrity (Fig. 5A), animals treated with ATWLPPR NRP-1 inhibitor had significantly higher levels of occludin in microvessels when compared with sterile PBS-treated animals (PBS n = 6, 3 mg n = 9) (Fig. 5C). These results demonstrate that inhibition of NRP-1 in vivo preserves occludin protein levels in CNS microvessels in the PIFS model.

Perforin is required for VEGF upregulation

Despite having similar CNS infiltration of D\(^{b}\);VP2121–130 Ag-specific CD8 T cells in the brain of wild-type animals, perforin-deficient C57BL/6 mice did not exhibit BBB tight junction protein alterations or CNS vascular permeability in the PIFS model.
To determine the extent VEGF upregulation is dependent on perforin, 7-d TMEV-infected C57BL/6 perforin−/− mice were administered VP2121-130 or mock E7 peptide and assessed for CNS vascular permeability and VEGF expression. In Fig. 6, we demonstrate that there are no differences in VEGF mRNA expression and anatomical location between the E7 peptide (Fig. 6A) and VP2121-130 peptide treated-animals (Fig. 6B). Similarly, we semiquantitatively analyzed VEGF mRNA in the SG of the hippocampal dentate gyrus (Fig. 6C) and VEGF protein in the whole brain (Fig. 6D) and found no significant differences when compared with the dramatic increases observed in perforin competent wild-type mice in the PIFS model (Fig. 4F). These results demonstrate that perforin is necessary for CD8 T cell-mediated upregulation of VEGF in the CNS and the ensuing vascular permeability syndrome.

**Discussion**

VEGF-mediated processes have been implicated in numerous disease states, including cerebral malaria, DHF, traumatic brain injury, meningococcal septic shock, cancer metastases, stroke, and MS (30, 32, 33, 35, 52–54). The results of the current studies demonstrate an in vivo role for VEGF in BBB dysregulation and CNS vascular permeability under neuroinflammatory conditions. Using this model, we have also demonstrated that CD8 T cells can initiate upregulation of neuronal expression of VEGF in the CNS through a process requiring perforin expression. To our knowledge,
we are the first to demonstrate modulation of VEGF expression in neurons through stimulating CNS-infiltrating CD8 T cells.

Clinical studies of human cerebral malaria have shown that the BBB is altered during infection similar to results observed in our model (6). Animal models of cerebral malaria have put forth the hypothesis that CD8 T cells are involved in neuropathology and CNS vascular permeability (16). Interestingly, studies using tissue from human cerebral malaria patients show a prominent population of VEGF-expressing cells in the CNS when compared with controls, suggesting a role for this protein in the neuropathology associated with this disease (33). Unlike human and mouse cerebral malaria models, the CD8 T cell-specific Ag has been identified in our system. This is advantageous as it enables us to determine the kinetics of inflammatory mediators downstream of stimulation of CNS-infiltrating CD8 T cells to serve as a model for human neurologic diseases that imply a causal role for CD8 T cells. BBB disruption in this model is specifically the result of the CD8 T cell reaction to i.v. administration of TMEV-derived VP2121–130 peptide Ag.

Human viral hemorrhagic fevers also present with abnormal CD8 T cell activity. In DHF, Ag-specific CD8 T cell activation and expansion can be measured in the blood of patients during the peak of this fatal hemorrhagic syndrome (10). It has been put forward that VEGF and VEGFR2, the human homolog of flk-1, may play an important role in this condition. Studies of plasma in human dengue patients have shown that vascular permeability is inversely correlated with the amount of soluble VEGFR2. Levels of plasma soluble VEGFR1 were stable, indicating that VEGFR2 is the key receptor involved in DHF (35). When these studies were evaluated using an in vitro system, it was demonstrated that the dengue virus suppressed soluble VEGFR2 levels, while promoting increased levels of membrane-bound VEGFR2 (35). These findings are intriguing and suggest that increased levels of membrane bound VEGFR2 may lead to enhanced signaling of vascular permeability-inducing pathways during dengue infection (35). To determine the extent that VEGF-related pathways potentiated vascular permeability in the PIFS model, we first sought to determine the cellular source and time course of VEGF upregulation. To determine this, we used Western blot and in situ hybridization techniques. Our results indicate that VEGF protein and flk-1 activation are significantly increased in the PIFS model by 4 h post-VP2121–130 administration, coinciding with the onset of CNS vascular permeability.

We determined in these studies that neurons rapidly upregulated VEGF after induction of PIFS. We semiquantitatively analyzed VEGF mRNA expression in the SG of the hippocampal dentate gyrus and found that VEGF mRNA was significantly increased by 2 h postadministration of VP2121–130 and continued to be significant through 24 h. VEGF expression therefore preceded and coincided with vascular permeability. We therefore i.v. administered a NRP-1 inhibitor, ATWLPPR, which has been shown to prevent flk-1-mediated mechanisms in vitro and in vivo (50, 51). NRP-1 is a nonreceptor kinase VEGF receptor that enhances VEGF binding to flk-1 and subsequent flk-1-mediated mechanisms (47, 50, 55).

Our results demonstrate that i.v. administration of high doses of ATWLPPR preserves CNS vascular integrity in this model as assessed by comparing leakage of FITC-albumin into the brain with saline- and scrambled peptide-treated animals. The results of these experiments provide evidence that engagement of VEGF with its receptors, NRP-1 and flk-1 significantly contributes to CD8 T cell-driven CNS vascular permeability.

Tight junction protein expression in microvessels is dynamically altered after induction of PIFS (22). In particular, levels of tight junction protein occludin are rapidly reduced in brain microvessels after induction of CD8 T cell-mediated CNS vascular permeability (22). The importance of occludin and other tight junction proteins in BBB disruption is an emerging area of research. There are currently three models in which occludin is modified during BBB disruption: 1) phosphorylation by p kinases (56), 2) altered location in vascular endothelial cells (57), and 3) reduction in total protein levels (22, 40, 58). These three models are not mutually exclusive of one another, as both phosphorylation and reduction of occludin have been reported simultaneously in BBB dysregulation (59). Here, we demonstrate that peptide inhibition of the interaction of VEGF with NRP-1 results in preservation of occludin protein when compared with the saline controls at 24 h postinduction of PIFS (Fig. 5). This finding further supports a working model in which preserved occludin protein levels contribute to maintaining an impermeable BBB. These data also support the concept that VEGF-related signal transduction through NRP-1 and flk-1 contributes to
alterations in microvessel occludin protein levels in T cell-induced BBB disruption.

Recently, we reported that the immune effector protein, perforin, was necessary for CNS vascular permeability to occur in this model (22). Perforin, a cytolytic protein, is used by CD8 (cytotoxic) T lymphocytes and NK cells to deliver inflammatory mediators that control virus infection (60). In this study, we demonstrate that VEGF upregulation is dependent on perforin expression. This observation necessitates further analysis of the cellular source of perforin and defining the critical agent delivered through this pathway. Similar to our studies, Kim et al. observed a reduction in CNS vascular permeability in perforin-deficient lymphocytic choriomeningitis virus-infected mice (61). However, the authors concluded that delayed onset of CNS vascular permeability in perforin-deficient mice was due to reduced infiltration of CD8 T cells into the CNS (61, 62). The authors instead concluded through GR-1 depletion strategies that neutrophils were the critical blood-derived cell type promoting BBB disruption. However, our studies do not support this hypothesis. In previous studies with this model, we demonstrate similar levels of CNS infiltration of Ag-specific CD8 T cells using perforin directly engage neurons to promote VEGF upregulation. Neuronal processes are an integral part of the neurovascular unit (70). Therefore, neurally expressed VEGF could be delivered to CECs and alter tight junctions of the BBB. Our indirect hypothesis entails an alternative cell type in the CNS which then induces VEGF expression. VEGF expression is not exclusive to neurons, leaving the potential for other CNS cell types, endothelial cells, and immune cells to contribute to BBB disruption through expression of this cytokine (71). Induction of VEGF through either the direct and indirect pathways outlined previously promotes vascular permeability through flk-1/NRP-1 receptor-mediated signal transduction. This, likely, results in MMP protease activity and BBB tight junction alterations and vascular permeability. Assessment of the direct and indirect mechanisms in vivo requires the development of the appropriate conditional knockout mice which are currently under development. Nevertheless, the data put forward provide rationale for the inhibition of VEGF-mediated pathways as a therapeutic strategy designed to treat neurologic conditions associated with immune-mediated CNS vascular permeability.

**Acknowledgments**

We thank Scott Holland and Scott Dunn of Cincinnati Children’s Hospital and Medical Center for MRI technical assistance, Nancy Kleene and Birgit Ehmer of the University of Cincinnati for microscopy expertise, Tracy A. Brooks and Thomas P. Davis of the University of Arizona for assistance with the microvessel isolation protocol. Finally, we thank Lawrence F. Brown of Harvard for kindly providing VEGF probes for in situ hybridization.